Feature | September 05, 2013

Cardiac Resychronization Therapy Fails for Certain Heart Failure Patients

The EchoCRT trial was ended early to prevent harm to patients

September 5, 2013 — Researchers announced this week that an attempt to expand cardiac resynchronization therapy (CRT) to include more patients with heart failure has failed and an international clinical trial ended early to prevent potential harm to patients. 
The Echocardiography Guided Cardiac Resynchronization Therapy (EchoCRT) is the largest international, multicentre, prospective, randomized, double-blind, clinical trial of its kind. Results of the trial are available online by the New England Journal of Medicine and were presented during this week’s Late Breaking Clinical Trials session at the European Society of Cardiology Congress in Amsterdam, Netherlands.
The trial found the widespread off-label use of CRT in patients with narrow QRS should no longer be used as an option for patients with a QRS below 130 milliseconds, regardless of mechanical dyssynchrony. This trial serves as a reminder that in clinical medicine adequately powered definitive clinical outcome trials are needed before we expand the use of an apparently favorable therapy.
“Cardiac resynchronization therapy is a proven treatment for people who have a type of heart failure that includes an electrical abnormality, or a wide QRS complex,” said William Abraham, M.D., director of the division of cardiovascular medicine at The Ohio State University Wexner Medical Center and national co-principal investigator of the study. “We noticed some cardiologists were also trying CRT in heart failure patients who did not have this electrical abnormality, however no large studies had tested the use of CRT in this way.”
In 2008, cardiovascular researchers at 115 centers in Europe, Australia and the United States teamed up to test the safety and efficacy of CRT in heart failure patients who had a narrow QRS complex. Patients were enrolled in the study if they had an ejection fraction of 35 percent or less, a narrow QRS duration of 130 milliseconds or less and echocardiographic evidence of a left ventricular dyssynchrony. A total of 809 study participants underwent implantation of a cardiac resynchronization device with defibrillator capability developed by Biotronik. Half (404) were randomized to have CRT turned on while the other half (405) did not receive CRT. All study participants had the defibrillator capability turned on.
After following each participant an average of 19 months, the trial was stopped in March on the basis of futility and potential for harm. Researchers recorded 45 deaths and 224 hospitalizations for worsening heart failure in the CRT group compared to 26 deaths and 194 hospitalizations in the control group. 
“Not only did cardiac resynchronization not help these patients with systolic heart failure, but the data showed the potential for harm,” said Abraham. “This is a landmark trial in CRT and heart failure because it tells us we should not use this therapy in this group of patients.”
Heart failure occurs when the heart does not pump blood efficiently, most often due to a weak heart muscle. Patients suffer from shortness of breath, fatigue, swelling and reduced quality of life. According to the American Heart Association, about 5.7 million Americans have heart failure and it accounts for about 1 million hospital admissions each year at an estimated societal cost of $32 billion.
“We’re always looking for better treatments for patients with heart failure to improve their quality of life and reduce their hospitalizations,” said  Ayesha Hasan, M.D., a heart failure cardiologist at Ohio State’s Richard M. Ross Heart Hospital and the lead principal investigator at Ohio State. “We now know expanding the use of CRT in this population of patients is not a positive solution.”
Abraham says researchers are still investigating why CRT did not work for this group of patients, to better understand the benefits and challenges of this treatment option.
“The EchoCRT trial evaluated an important question for daily clinical practice.  The results will help to guide physicians’ treatment decisions for heart failure patients moving forwards.” said co-lead investigator Johannes Holzmeister, M.D., from University Hospital in Zurich, Switzerland.
Biotronik funded the FDA-approved trial. Abraham is a paid consultant for the company.
For more information: bit.ly/1buTeHk

Related Content

News | Heart Failure| October 02, 2015
Cyberonics Inc. announced results from the extension of the ANTHEM-HF clinical study (ENCORE Study). Results of the...
Tryton Side Branch Stent, clinical trial results, Catheterization and Cardiovascular Interventions

Tryton Side Branch Stent image courtesy of Tryton Medical

News | Stents Bifurcation| October 02, 2015
October 2, 2015 — Tryton Medical Inc.
AtriCure, cryoFORM cryoablation probe, launch
Technology | Ablation Systems| October 02, 2015
AtriCure Inc. launched the cryoFORM cryoablation probe, which offers increased probe flexibility to adapt to a variety...
Intact Vascular, TOBA II study, Tack Endovascular System

Image courtesy of Intact Vascular

News | Peripheral Arterial Disease (PAD)| October 01, 2015
Intact Vascular Inc. announced the U.S. Food and Drug Administration has granted conditional approval for a U.S. and...
Johns Hopkins, sticky gel, stem cells, rat hearts, heart attacks

Hydrogel applied to beating rat hearts improves stem cell uptake by the heart muscle and speeds up tissue healing after heart attack. Image courtesy of Johns Hopkins Medicine.

News | Stem Cell Therapies| September 29, 2015
A sticky, protein-rich gel created by Johns Hopkins researchers appears to help stem cells stay on or in rat hearts and...
News | Cath Lab| September 29, 2015
The Innovation Institute announced that Boston Scientific has signed an agreement to become the founding medical device...
Eluvia drug-eluting vascular stent system, 12-month primary patency, Boston Scientific, MAJESTIC trial, CIRSE

Image courtesy of Boston Scientific

News | Stents Peripheral| September 28, 2015
New 12-month clinical trial outcomes assessing the safety and performance of the Boston Scientific Eluvia drug-eluting...
predicting arrhythmias, mcgill university, alternans patterns
News | EP Lab| September 28, 2015
Researchers have discovered how to predict some cardiac arrhythmias several steps before they even occur. It’s a...
News | Antiplatelet and Anticoagulation Therapies| September 25, 2015
The Icahn School of Medicine at Mount Sinai has launched the international TWILIGHT clinical trial to test the safety...
Medisafe, medication management, mHealth platform, blood pressure study, hypertension, adherence
News | Hypertension| September 25, 2015
Medisafe, an mHealth platform for medication management, announced the results of its blood pressure study, which...
Overlay Init